![]() CTNC has a tradition of excellence in clinical research, having participated in over 50 clinical trials. All of us at CTNC want our patients to be aware of our dedication to clinical research. Our physicians have extensive experience and are committed to advancing medical science through clinical research studies.
What is Clinical Research?
The National Institutes of Health defines “clinical research” as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects. Excluded from this definition are in vitro studies that utilize human tissues that cannot be linked to a living individual.Clinical research includes:
If you are interested in participating in one of our clinical trials, please submit a research patient enrollment form. ACTIVE TRIALS: ENROLLING
ACTIVE TRIALS: ONGOINGAlzheimer's Disease:
ANVS-22001
A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy, safety, and tolerability of two different doses of buntanetap or placebo in patients with early Parkinson’s disease
Status: Ongoing | Not Enrolling
BN42358
A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter study to evaluate the efficacy and safety of intravenous Prasinezumab in participants with early Parkinson’s Disease
Status: Ongoing | Not EnrollingBP39529
A Randomized, Double-Blind, Placebo- Controlled 52 week phase II Study to evaluate the efficacy of IV RO7046015 (PRX002) in participants with early Parkinson’s disease safety and tolerability of ABBV-951 in subjects with Parkinson's Disease
Status: Ongoing | Not Enrolling
CVL-751-PD-003
A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel-Group, Flexible-Dose, 27-Week trial to evaluate the efficacy, safety, and tolerability of Tavapadon as adjunctive therapy for Parkinson’s Disease in Levodopa-treated adults with motor fluctuations (TEMPO-3 TRIAL)
Status: Ongoing | Not Enrolling
CVL-751-PD-004
58-Week open-label Trial of Tavapadon in Parkinson’s Disease
Status: Ongoing | Not Enrolling
UPCOMING TRIALS:CN008-0003
A Phase 2, Randomized, double-lind, placebo-controlled, Multicenter study assessing the efficacy, safety and tolerability of BMS-986446, and Anti-MTBR Tau Monoclonal Antibody, in participants with Early Alzheimer’s Disease. FNP223-CT-2301
A randomized, double-blind placebo-controlled, study to asses the safety, efficacy, and pharmacokinetics of FNP-223 (oral formulation) for the treatment of Progressive Supranuclear Palsy. TV56286-NDG-20039
A Multi-centered, double-blind, Randomized, Placebo-controlled, Parallel group Phase 2 study pf TEV-562 for the treatment of patients with Multiple system atrophy. |
RESEARCH TEAM
Learn More
Clinical Research Resources
|